Stanford Cancer Institute
Cancer Cell Therapy

Multiple Myeloma

Newly Diagnosed

Post-Auto

Relapsed

Auto

CCT5077
Phase III Randomized Study Comparing DVPd) followed by Cicitacabtagene Autoleucel vs DVPd followed by Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma who are Transplant Eligible
PI: Sidana Sponsor: European Myeloma Network

CCT5054
Phase II Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma in Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide
PI: Sidana Sponsor: BMT CTN

CCT5097
Phase I Open-Label Dose-Finding Study of BMS-986453 Dual Targeting BCMxGPRC3D Chimeric Antigen Receptor T Cells, in Relapsed and/or Refractory Multiple Myeloma
PI: Sidana Sponsor: Bristol-Myers Squibb

CCT5030
Phase I ALLO-715 Eval Anti-RBMA Allogeneic CAR T Cell Tx in Relapsed/Refractory Multiple Myeloma
PI: Liedtke Sponsor: Allogene Therapeutics

CCT5070
Phase II PHE885 B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Relapsed and Refractory Multiple Myeloma
PI: Sidana Sponsor: Novartis Pharmaceuticals Corporation

CCT5093
Talquetamab US Expanded Access Treatment Protocol in Relapsed or Refractory Multiple Myeloma
PI: Sidana Sponsor: Celgene Corporation

CCT5056
Expanded Access Protocol (EAP) in Idecabtagene Vicleucel that is Non-comforming for Commercial Release
PI: Sidana Sponsor: Janssen Research & Development, LLC

CCT5091
Intermediate-Size Population Expanded Access Program (EAP) for Cicitacabtagene Autoleucel (Cita-Cell) Out-of-Specification (OOS) in Multiple Myeloma
PI: Sidana Sponsor: Janssen Research & Development, LLC

Note: CCT5091 closes when CCT5091 opens